Such a condition induces an increase in de novo synthesis of cholesterol that does not correct hypocholesterolemia because the alteration in CFTR reduces the blood release of cholesterol, causing the accumulation of liver cholesterol that contributes to inflammation, as observed in the CF mouse model (Amato et al., 2021). This evidence concerns the gene CFTR and cystic fibrosis.